BioSpace News Archive

Pictured: Elizabeth Holmes/Courtesy Yichuan Cao/Nu

Policy

Elizabeth Holmes Denies Destroying Critical Database in Pretrial Arguments

The prosecution alleged that sometime in 2018, Holmes destroyed a database called the Laboratory Information System (LIS), which contained three years’ worth of accuracy and failure rates of Theranos tests.

February 24, 2021

·

3 min read

·

Alex Keown

Genetown

Novavax’s Uphill Battle to Vaccine Success

Even with its potential technical advantages, Novavax has some challenges.

February 24, 2021

·

4 min read

·

Mark Terry

Orna Chief Executive Officer, Thomas Barnes.

Business

Orna Therapeutics Circles Success With $100 Million Launch

Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.

February 24, 2021

·

3 min read

·

Heather McKenzie

Doppler Technique Allows Researchers to “Peek” Into Cells, Identify Antibiotic-Resistant Pathogens

Scientists from Purdue University are using Doppler radar to “peek” into cells and monitor metabolic activity in real time, allowing them to test microbes, detect pathogens in different environments and identify potential treatments for antibiotic-resistant bacteria.

February 24, 2021

·

3 min read

·

Brandon May

Policy

With Supply Lagging, COVID-19 Vaccine Manufacturers Pledge to Ramp Up

Although problems with actually getting shots into arms have been described thoroughly, manufacturing problems and scale-up haven’t been the focus of much reporting.

February 24, 2021

·

5 min read

·

Mark Terry

Business

Bristol Myers Inches Toward the Future of Cell Therapy with New Manufacturing Plant

BMS is looking to hire “several hundred employees over the next few years,” all working to ensure the production of both their clinical and commercial cell therapies.

February 24, 2021

·

2 min read

·

Kristiane Polido

Business

BioSpace Global Roundup: UCB and Microsoft Pair AI and Drug Discovery Technology

Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.

February 24, 2021

·

6 min read

·

Alex Keown

Drug Development

FDA Puts bluebird bio’s LentiGlobin on Clinical Hold

The hold comes just after patient dosing began in HGB-210, the company’s Phase III single-arm open-label LentiGlobin trial for SCD patients between the ages of 2 and 50.

February 24, 2021

·

2 min read

·

Mark Zipkin